These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Iron Oxide Nanoparticles Decorated with Functional Peptides for a Targeted siRNA Delivery to Glioma Cells. Chung S; Sugimoto Y; Huang J; Zhang M ACS Appl Mater Interfaces; 2023 Jan; 15(1):106-119. PubMed ID: 36442077 [TBL] [Abstract][Full Text] [Related]
7. Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. Agnihotri S; Gajadhar AS; Ternamian C; Gorlia T; Diefes KL; Mischel PS; Kelly J; McGown G; Thorncroft M; Carlson BL; Sarkaria JN; Margison GP; Aldape K; Hawkins C; Hegi M; Guha A J Clin Invest; 2012 Jan; 122(1):253-66. PubMed ID: 22156195 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma. Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370 [TBL] [Abstract][Full Text] [Related]
9. The nanoprodrug of polytemozolomide combines with MGMT siRNA to enhance the effect of temozolomide in glioma. Xu H; Zhang Y; Li L; Ren Y; Qian F; Wang L; Ma H; Quan A; Liu H; Yu R Drug Deliv; 2023 Dec; 30(1):1-13. PubMed ID: 36579448 [TBL] [Abstract][Full Text] [Related]
10. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma. Chen Z; Wei X; Shen L; Zhu H; Zheng X Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207 [TBL] [Abstract][Full Text] [Related]
11. Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting. Wang L; Tang S; Yu Y; Lv Y; Wang A; Yan X; Li N; Sha C; Sun K; Li Y Mol Pharm; 2021 Mar; 18(3):915-927. PubMed ID: 33417456 [TBL] [Abstract][Full Text] [Related]
13. Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells. Kato T; Natsume A; Toda H; Iwamizu H; Sugita T; Hachisu R; Watanabe R; Yuki K; Motomura K; Bankiewicz K; Wakabayashi T Gene Ther; 2010 Nov; 17(11):1363-71. PubMed ID: 20520650 [TBL] [Abstract][Full Text] [Related]
14. Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells. Taspinar M; Ilgaz S; Ozdemir M; Ozkan T; Oztuna D; Canpinar H; Rey JA; Sunguroğlu A; Castresana JS; Ugur HC Tumour Biol; 2013 Jun; 34(3):1935-47. PubMed ID: 23519841 [TBL] [Abstract][Full Text] [Related]
15. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma. Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605 [TBL] [Abstract][Full Text] [Related]
16. Dual bioluminescence and near-infrared fluorescence monitoring to evaluate spherical nucleic acid nanoconjugate activity in vivo. Sita TL; Kouri FM; Hurley LA; Merkel TJ; Chalastanis A; May JL; Ghelfi ST; Cole LE; Cayton TC; Barnaby SN; Sprangers AJ; Savalia N; James CD; Lee A; Mirkin CA; Stegh AH Proc Natl Acad Sci U S A; 2017 Apr; 114(16):4129-4134. PubMed ID: 28373576 [TBL] [Abstract][Full Text] [Related]